Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GIM-122 by Georgiamune for Solid Tumor: Likelihood of Approval
GIM-122 is under clinical development by Georgiamune and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...